Regis Healthcare Limited

ASX:REG Stock Report

Market Cap: AU$2.0b

Regis Healthcare Valuation

Is REG undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of REG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: REG (A$6.48) is trading below our estimate of fair value (A$14.22)

Significantly Below Fair Value: REG is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for REG?

Key metric: As REG is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for REG. This is calculated by dividing REG's market cap by their current revenue.
What is REG's PS Ratio?
PS Ratio1.9x
SalesAU$1.01b
Market CapAU$2.02b

Price to Sales Ratio vs Peers

How does REG's PS Ratio compare to its peers?

The above table shows the PS ratio for REG vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.3x
MVF Monash IVF Group
1.7x6.4%AU$440.3m
RHC Ramsay Health Care
0.5x4.4%AU$8.7b
PSQ Pacific Smiles Group
1.7x7.2%AU$312.0m
SIG Sigma Healthcare
1.2x21.5%AU$4.1b
REG Regis Healthcare
1.9x7.9%AU$2.0b

Price-To-Sales vs Peers: REG is expensive based on its Price-To-Sales Ratio (1.9x) compared to the peer average (1.3x).

Price to Sales Ratio vs Industry

How does REG's PS Ratio compare vs other companies in the AU Healthcare Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
FCG Freedom Care Group Holdings
0.1xn/aUS$2.60m
HHI Health House International
0.05xn/aUS$590.30k
TTB Total Brain
0.03xn/aUS$179.68k
No more companies available in this PS range
REG 1.9xIndustry Avg. 1.4xNo. of Companies3PS00.81.62.43.24+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: REG is expensive based on its Price-To-Sales Ratio (1.9x) compared to the Oceanic Healthcare industry average (1.4x).

Price to Sales Ratio vs Fair Ratio

What is REG's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

REG PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.9x
Fair PS Ratio1.1x

Price-To-Sales vs Fair Ratio: REG is expensive based on its Price-To-Sales Ratio (1.9x) compared to the estimated Fair Price-To-Sales Ratio (1.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst REG forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$6.48
AU$6.54
+0.9%
14.0%AU$7.50AU$4.46n/a7
Nov ’25AU$6.40
AU$6.46
+0.9%
14.9%AU$7.50AU$4.46n/a6
Oct ’25AU$6.24
AU$6.46
+3.5%
14.9%AU$7.50AU$4.46n/a6
Sep ’25AU$5.13
AU$4.78
-6.9%
13.8%AU$5.50AU$3.50n/a6
Aug ’25AU$4.23
AU$4.41
+4.2%
16.4%AU$5.50AU$3.45n/a6
Jul ’25AU$4.22
AU$4.37
+3.4%
15.0%AU$5.50AU$3.60n/a6
Jun ’25AU$3.97
AU$4.30
+8.3%
14.9%AU$5.50AU$3.60n/a6
May ’25AU$3.80
AU$4.00
+5.2%
9.8%AU$4.60AU$3.45n/a6
Apr ’25AU$4.01
AU$4.00
-0.3%
9.8%AU$4.60AU$3.45n/a6
Mar ’25AU$3.49
AU$3.84
+10.0%
6.3%AU$4.20AU$3.45n/a6
Feb ’25AU$3.23
AU$3.52
+8.9%
7.2%AU$3.90AU$3.10n/a6
Jan ’25AU$3.25
AU$3.20
-1.6%
8.4%AU$3.50AU$2.65n/a7
Dec ’24AU$2.85
AU$3.11
+9.0%
7.2%AU$3.38AU$2.65n/a7
Nov ’24AU$2.50
AU$2.77
+10.7%
5.9%AU$3.00AU$2.45AU$6.407
Oct ’24AU$2.70
AU$2.52
-6.8%
14.9%AU$3.00AU$1.89AU$6.248
Sep ’24AU$2.50
AU$2.52
+0.7%
14.9%AU$3.00AU$1.89AU$5.138
Aug ’24AU$2.26
AU$2.45
+8.3%
17.2%AU$3.40AU$1.89AU$4.238
Jul ’24AU$2.22
AU$2.50
+12.8%
17.0%AU$3.40AU$1.89AU$4.227
Jun ’24AU$2.29
AU$2.33
+1.7%
21.5%AU$3.40AU$1.75AU$3.977
May ’24AU$2.17
AU$2.16
-0.3%
25.6%AU$3.40AU$1.60AU$3.807
Apr ’24AU$1.95
AU$2.16
+11.3%
25.6%AU$3.40AU$1.60AU$4.017
Mar ’24AU$1.56
AU$2.20
+41.2%
24.6%AU$3.40AU$1.60AU$3.497
Feb ’24AU$1.70
AU$2.25
+32.7%
20.2%AU$3.10AU$1.55AU$3.237
Jan ’24AU$1.89
AU$2.36
+25.3%
15.8%AU$3.10AU$1.95AU$3.257
Dec ’23AU$1.98
AU$2.36
+19.3%
15.8%AU$3.10AU$1.95AU$2.857
Nov ’23AU$2.05
AU$2.36
+15.2%
15.8%AU$3.10AU$1.95AU$2.507

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

SDI

AU$122.4m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.03

7D

-4.2%

1Y

30.4%

CardieX

AU$30.9m

Engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific.

CDX

AU$0.10

7D

-22.2%

1Y

n/a

Nova Eye Medical

AU$34.4m

Designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally.

EYE

AU$0.15

7D

1.7%

1Y

17.3%